photo courtesy of Valley Hospital
the staff of the Ridgewood blog
Ridgewood NJ, Valley is proud to recognize the clinical team that has treated more than 500 COVID-19 patients with monoclonal antibody infusion, which is administered to reduce progression of the virus and prevent hospitalizations.
Monoclonal antibody (mAb) therapy, also called monoclonal antibody infusion treatment, is a way of treating COVID-19. The goal of this therapy is to help prevent hospitalizations, reduce viral loads and lessen symptom severity. This type of therapy relies on monoclonal antibodies.
Monoclonal antibody treatment is for high-risk patients with mild to moderate COVID-19 infection who are within 10 days of symptom onset. The treatment involves a single infusion of monoclonal antibodies, laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens, such as viruses. The monoclonal antibody-based medication is designed to bind to the coronavirus, preventing it from invading cells. We thank you all for your role in caring for our patients with COVID-19.